AstraZeneca holds talks with Bristol Myers Squibb over $400bn merger
AstraZeneca, Britain's biggest drugmaker, is in talks to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group. The tie-up would rank among the largest pharmaceutical mergers ever and would create the world's fourth-biggest drugmaker by market value, significantly expanding AstraZeneca's presence in the United States, where it is already committed to $50bn in research and manufacturing investment by 2030. Talks have reportedly been under way for several months, though sources caution there is no certainty a deal will be finalised.
AstraZeneca, led by chief executive Pascal Soriot and headquartered in Cambridge, is the second-largest listed company in the UK with a market value of nearly £196bn, while New Jersey-based BMS, known for its cancer treatments, is worth $133bn. The approach comes shortly after AstraZeneca reaffirmed confidence in hitting 2030 sales targets of $80bn despite a setback with an experimental heart disease drug, and after BMS posted stronger-than-expected quarterly results, with revenues up 5% to $12.97bn. AstraZeneca declined to comment on the talks, which were first reported by the Financial Times, and BMS has yet to respond.
- AstraZeneca in talks to buy Bristol Myers Squibb in near-$400bn deal
- Merger would create world's fourth-largest drugmaker by value
- Deal still uncertain; both companies declined or didn't comment
New here? Start with this
AstraZeneca is Britain's biggest pharmaceutical company, based in Cambridge and led by chief executive Pascal Soriot. Bristol Myers Squibb is a major US drugmaker based in New Jersey, best known for its cancer treatments. Reports say the two firms have held talks about AstraZeneca taking over its American rival, though no deal has been agreed and there is no guarantee one will be.
A merger of this size would be one of the largest in pharmaceutical history, combining two companies worth roughly £196bn and $133bn respectively to create a group valued at nearly $400bn, and the world's fourth-biggest drugmaker by market value. It would also deepen AstraZeneca's footprint in the United States, where it has already pledged $50bn towards research and manufacturing by 2030.
The talks come as both companies are under pressure to demonstrate strong growth: AstraZeneca has set itself a target of $80bn in annual sales by 2030, while BMS has just reported better-than-expected quarterly earnings. Neither company has confirmed the discussions publicly, and the report originated with the Financial Times.
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Proponents of the tie-up argue that combining AstraZeneca's global reach with Bristol Myers Squibb's strong oncology portfolio would create a more resilient, diversified group better able to absorb the cost and risk of drug development. Scale of this kind, they contend, allows greater investment in research and manufacturing, supports the sort of long-term commitments AstraZeneca has already made in the US, and strengthens its position against larger American rivals in an increasingly competitive global pharmaceutical market. For shareholders and employees alike, a successful merger could secure the company's standing as a world-leading drugmaker for decades to come.
The case against
Sceptics of the deal caution that mega-mergers in pharmaceuticals frequently bring painful integration, duplicated research programmes and job losses, with cost-cutting sometimes taking precedence over innovation. There are also broader concerns about consolidation reducing competition within the industry, which critics warn can, over time, contribute to higher drug prices and fewer independent research pathways. Some observers further worry about what a deal of this size means for the UK, given AstraZeneca's status as Britain's largest listed company, questioning whether an increasingly US-weighted footprint could dilute its ties to, and investment in, its home market.
Americas Business Companies Geopolitics Health Medicine Politics Software Technology UK World